Adma Biologics | ADMA - Ebitda

Aktienkurs
9.36
Täglich Wechseln
0.17 1.85%
Monatlich
-40.80%
Jährlich
-49.13%
Q2 Prognose
8.91




Ebitda Veränderung Datum
Adma Biologics USD 73.59M 14.85M 2025-12
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
BioCryst Pharmaceuticals USD 51.7M 30.14M 2025-09
Minerva Neurosciences USD -4.36M 1.71M 2024-09
Novavax USD 19.36M 190.79M 2025-12
Omeros USD -47.96M 7.39M 2023-09
Takeda JPY 448.13B 173.98B 2025-12